BE
BEIGF.US BeiGene Ltd.
- Market cap
- USD 32.6B
- P/E
- 51.0x
- P/B
- 6.24x
- ROE
- 19.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BEIGF.US undervalued?
Graham numberThe Graham number of BeiGene Ltd. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BeiGene Ltd. fundamental analysis
No fundamental analysis for BeiGene Ltd. yet.
BeiGene Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BeiGene Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult…
Full company profileBeiGene Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BeiGene Ltd. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 198M | 428M | 309M | 1.18B | 1.42B | 2.46B | 3.81B | 5.34B | 6.81B |
| Gross Profit | -509M | -570M | 238M | 1.01B | 1.13B | 2.08B | 3.22B | 4.67B | 6.07B |
| Operating Income | -706M | -960M | -1.66B | -1.44B | -1.79B | -1.21B | -568M | 447M | 1.32B |
| EBITDA | -695M | -941M | -1.63B | -1.39B | -1.72B | -734M | 172M | 617M | 1.05B |
| Net Income | -674M | -949M | -1.62B | -1.46B | -2.00B | -882M | -645M | 287M | 1.13B |
| EPS | -0.87 | -1.18 | -1.36 | -1.09 | -1.48 | -0.65 | -0.47 | 0.19 | 0.74 |
| Balance Sheet | |||||||||
| Total Assets | 2.25B | 1.61B | 5.60B | 8.54B | 6.38B | 5.81B | 5.92B | 8.19B | 9.88B |
| Total Liabilities | 496M | 634M | 1.73B | 2.40B | 2.00B | 2.27B | 2.59B | 3.83B | 4.06B |
| Shareholders' Equity | 1.75B | 978M | 3.87B | 6.13B | 4.38B | 3.54B | 3.33B | 4.36B | 5.82B |
| Cash & Short-term Investments | 713M | 618M | 1.38B | 4.38B | 3.87B | 3.17B | 2.63B | 4.55B | 5.78B |
| Total Debt | - | - | - | - | - | - | 1.08B | 1.09B | 1.15B |
| Cash Flow | |||||||||
| Operating Cash Flow | -548M | -750M | -1.28B | -1.30B | -1.50B | -1.16B | -141M | 1.13B | 1.56B |
| Capital Expenditure | 141M | 159M | 227M | 315M | 469M | 596M | 493M | 186M | 138M |
| Free Cash Flow | -689M | -909M | -1.51B | -1.61B | -1.97B | -1.75B | -633M | 942M | 1.43B |
| Ratios | |||||||||
| ROE | -38.4% | -97.0% | -42.0% | -23.8% | -45.7% | -24.9% | -19.4% | 6.6% | 19.5% |
| ROA | -29.9% | -58.8% | -29.0% | -17.1% | -31.4% | -15.2% | -10.9% | 3.5% | 11.5% |
| Net Profit Margin | -339.9% | -221.5% | -526.1% | -123.9% | -141.5% | -35.9% | -16.9% | 5.4% | 16.6% |
| Debt to Equity | - | - | - | - | - | - | 0.32x | 0.25x | 0.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BeiGene Ltd. dividends
BeiGene Ltd. has not paid dividends in the last 8 fiscal years.
Who owns BeiGene Ltd.
- Insiders 13.75%
- Institutions 29.16%
- Public & others 57.09%
- Shares outstanding 1.37B
- Free float 1.06B
BeiGene Ltd. company profile
- Company name
- BeiGene Ltd.
- Ticker
- BEIGF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12,000
- Fiscal year end
- December
- Address
- 94 Aeschengraben 27, Basel, Switzerland, 4051
- Phone
- 41 61 685 19 00
- Website
- beonemedicines.com
About BeiGene Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
BeiGene Ltd. management
10- Mr. John V. OylerCo-Founder, Executive Chairman & CEO · born 1968
- Mr. Wang Lai Ph.D.President and Global Head of Research & Development · born 1977
- Dr. Xiaodong Wang Ph.D.Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder · born 1963
- Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary · born 1968
- Mr. Titus B. BallVP & Chief Accounting Officer · born 1974
- Mr. Marcello DamianiChief Technology Officer · born 1970
- Ms. Liza HeapesHead of Investor Relations
- Ms. Eleanor Duff Ph.D.Senior VP & Head of Corporate Communications
- Mr. Graham HardimanGlobal Head of Human Resources
- Mr. Luo Lusong Ph.D.Head of External Innovation & Senior VP